NRAS amplification
|
CRC
|
NRAS amplification
|
CRC
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|
NRAS amplification
|
NSCLC
|
NRAS amplification
|
NSCLC
|
trametinib + infigratinib Resistant: D – Preclinical
|
trametinib + infigratinib Resistant: D – Preclinical
|
NRAS amplification
|
Melanoma
|
NRAS amplification
|
Melanoma
|
binimetinib Sensitive: D – Preclinical
|
binimetinib Sensitive: D – Preclinical
|
NRAS amplification
|
NSCLC
|
NRAS amplification
|
NSCLC
|
infigratinib Resistant: D – Preclinical
|
infigratinib Resistant: D – Preclinical
|